RISS 검색 - 국내학술지논문 상세보기

부가정보

다국어 초록 (Multilingual Abstract)

The purpose of this study was to compare plasma serotonin(5-HT) level in patients with major depressive disorder with in healthy normal control and investigate relationship between changes of plasma serotonin(5-HT) level and clinical improvement in patients with major depressive disorder. The subjects were thirty hospitalized patients with major depressive disorder who met DSM-Ⅳ(VPA 1994) diagnostic criteria and thirty healthy normal controls. Clinical evaluation with Hamilton Depression Rating Scale(HDRS) was done on admission and after 3 weeks of admission while the plasma serotonin(5-HT) level was checked at baseline, end of the 3rd weeks of treatment respectively.
The results were as follows :
1) There was no significant sex differences in plasma 5-HT level in both patient and control group.
2) In the plasma 5-HT level, the mean was 0.016±01012 in the patient of major depressive disorder and 0.104±0.059 in the control group, showing significant differences.
3) There was significant differences between plasma 5-HT level in the patients group of major depressive disorder in pretreatment and after 3 weeks of treatment.
4) There was significant differences between plasma 5-HT level in the patients group of major depressive disorder after 3 weeks of treatment and control group.
5) Relationship between plasma 5-HT changes and clinical improvement during 3 weeks of treatment was significantly correlated.
In summary, the present study was found significant differences in patients with major depressive disorder as compared with control group. And our results suggest that relationship between the changes of plasma 5-HT level and clinical improvement was significantly correlated in patients with major depressive disorder. Further studies are required to clarify the relationship between biochemical changes and clinical improvement.